An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).
Checked against the public recordLast updated May 20, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: Nivolumab; Biological: Ipilimumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease * Measurable disease by CT or MRI * Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work Exclusion Criteria: * Participants with untreated central nervous system metastases * Participants with active, known or suspected autoimmune disease * Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Local Institution - 0006Springdale, Arkansas
- Local Institution - 0001New Haven, Connecticut
- Local Institution - 0005Jacksonville, Florida
- Local Institution - 0009Atlanta, Georgia
- Local Institution - 0003St Louis, Missouri
- Local Institution - 0038The Bronx, New York
- Local Institution - 0002Cleveland, Ohio
- Local Institution - 0008Cleveland, Ohio
- Local Institution - 0007Greenville, South Carolina
- Local Institution - 0004Nashville, Tennessee
- Local Institution - 0017La Louvière, Hainaut
- Local Institution - 0018Ghent
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 20, 2024. Always confirm current availability with the study team.